Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.

about

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.

Item

http://www.wikidata.org/entity/Q54111915

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Lenvatinib inhibits angiogenes ...... patocellular carcinoma models.

@en

Lenvatinib inhibits angiogenes ...... patocellular carcinoma models.

@nl

type

Item

label

Lenvatinib inhibits angiogenes ...... patocellular carcinoma models.

@en

Lenvatinib inhibits angiogenes ...... patocellular carcinoma models.

@nl

prefLabel

Lenvatinib inhibits angiogenes ...... patocellular carcinoma models.

@en

Lenvatinib inhibits angiogenes ...... patocellular carcinoma models.

@nl

P1476

Lenvatinib inhibits angiogenes ...... epatocellular carcinoma models

@en

P2093

Junji Matsui

http://www.w3.org/2001/XMLSchema#string

Megumi Ikemori-Kawada

http://www.w3.org/2001/XMLSchema#string

Taisuke Hoshi

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Funahashi

http://www.w3.org/2001/XMLSchema#string

Yuji Yamamoto

http://www.w3.org/2001/XMLSchema#string

Yukinori Minoshima

http://www.w3.org/2001/XMLSchema#string

P2860

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Global cancer statistics, 2012

Sorafenib in advanced hepatocellular carcinoma

Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Hepatocellular carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.

P304

2641-2653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1517

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Masahiro Matsuki

P577

2018-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29733511

http://www.w3.org/2001/XMLSchema#string

P932

6010799

http://www.w3.org/2001/XMLSchema#string